Tags

Type your tag names separated by a space and hit enter

Effect of synbiotic supplementation on children with atopic dermatitis: an observational prospective study.
Eur J Pediatr. 2018 Dec; 177(12):1851-1858.EJ

Abstract

The objective of this observational single-cohort prospective study was to assess the effect of synbiotic supplementation for 8 weeks in children with atopic dermatitis (AD). The synbiotic product contained Lactobacillus casei, Bifidobacterium lactis, Lactobacillus rhamnosus, Lactobacillus plantarum, fructooligosaccharide, galactooligosaccharide, and biotin. Patients were examined at baseline and at 8 weeks. Effectiveness of treatment was assessed with the Scoring Atopic Dermatitis (SCORAD) index. A total of 320 children (mean age 5.1 years, range 0-12 years) were included. The mean (SD) SCORAD index decreased from 45.5 (15.5) at baseline to 19.4 (14.6) at the end of treatment (P < 0.001), VAS score for pruritus decreased from 5.7 (2.2) to 2.3 (2.2) (P < 0.001), and VAS score for sleep decreased from 3.1 (2.5) to 1.1 (1.8) (P < 0.001). Percentage of children with moderate-severe disease decreased from 92.4% at baseline to 28.1% at week 8. In the multiple linear regression analysis, higher baseline SCORAD index (OR 0.51; 95% CI 0.41-0.61) and higher adherence (OR 7.29; 95% CI 1.85-12.73) were significantly associated with greater decrease in SCORAD index.

Conclusion:

Supplementation with the multistrain synbiotic product may improve AD in children. What is known: • Pediatric atopic dermatitis (AD) is a common, troublesome condition with limited treatment options, which has been shown to be associated with dysbiosis in the intestinal microflora. • Results of controlled clinical trials (RCTs) on the effect of probiotics in children with AD have been disparate, although overall, the data favor probiotics over placebo, with multistrain supplements associated with better improvements in AD. What is new: • The results of this observational, prospective, open-label, single-cohort study on 320 children with AD younger than 12 years old suggest that supplementation with multistrain synbiotics (Lactobacillus casei, Bifidobacterium lactis, Lactobacillus rhamnosus, Lactobacillus plantarum, fructooligosaccharide, galactooligosaccharide, and biotin) helps to improve AD symptoms in children. • More than 80% of children experienced improvement in AD symptoms, as measured by Severity Scoring of Atopic Dermatitis (SCORAD) index and assessed by parents and physicians. The main predictive factors for improvement was adherence to synbiotic treatment and high baseline SCORE index; the change in SCORAD did not depend on age, gender, presence of concomitant treatment, duration, and type of AD (persistent vs with flares), other concomitant allergies or history of parental allergy.

Authors+Show Affiliations

Allergy Department and Biomedical Research Foundation (FIB), Hospital Infantil Universitario Niño Jesús, Avda. Menéndez Pelayo 56, E-28009, Madrid, Spain. mibanezs@salud.madrid.org. Health Research Institute, IIS Princesa, Madrid, Spain. mibanezs@salud.madrid.org. Allergy National Network (ARADyAL), Institute Carlos III, Madrid, Spain. mibanezs@salud.madrid.org.Allergy Department and Biomedical Research Foundation (FIB), Hospital Infantil Universitario Niño Jesús, Avda. Menéndez Pelayo 56, E-28009, Madrid, Spain. Health Research Institute, IIS Princesa, Madrid, Spain. Allergy National Network (ARADyAL), Institute Carlos III, Madrid, Spain.Medical department, Chiesi Spain S.A.U., Barcelona, Spain.Medical department, Chiesi Spain S.A.U., Barcelona, Spain.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study

Language

eng

PubMed ID

30259127

Citation

Ibáñez, M Dolores, et al. "Effect of Synbiotic Supplementation On Children With Atopic Dermatitis: an Observational Prospective Study." European Journal of Pediatrics, vol. 177, no. 12, 2018, pp. 1851-1858.
Ibáñez MD, Rodríguez Del Río P, González-Segura Alsina D, et al. Effect of synbiotic supplementation on children with atopic dermatitis: an observational prospective study. Eur J Pediatr. 2018;177(12):1851-1858.
Ibáñez, M. D., Rodríguez Del Río, P., González-Segura Alsina, D., & Villegas Iglesias, V. (2018). Effect of synbiotic supplementation on children with atopic dermatitis: an observational prospective study. European Journal of Pediatrics, 177(12), 1851-1858. https://doi.org/10.1007/s00431-018-3253-4
Ibáñez MD, et al. Effect of Synbiotic Supplementation On Children With Atopic Dermatitis: an Observational Prospective Study. Eur J Pediatr. 2018;177(12):1851-1858. PubMed PMID: 30259127.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of synbiotic supplementation on children with atopic dermatitis: an observational prospective study. AU - Ibáñez,M Dolores, AU - Rodríguez Del Río,Pablo, AU - González-Segura Alsina,Diego, AU - Villegas Iglesias,Vicenç, Y1 - 2018/09/26/ PY - 2018/04/10/received PY - 2018/09/12/accepted PY - 2018/09/12/revised PY - 2018/9/28/pubmed PY - 2018/11/21/medline PY - 2018/9/28/entrez KW - Bifidobacterium lactis KW - Lactobacillus casei KW - Lactobacillus plantarum KW - Lactobacillus rhamnosus KW - Pediatric atopic dermatitis KW - Probiotics KW - Synbiotics SP - 1851 EP - 1858 JF - European journal of pediatrics JO - Eur. J. Pediatr. VL - 177 IS - 12 N2 - The objective of this observational single-cohort prospective study was to assess the effect of synbiotic supplementation for 8 weeks in children with atopic dermatitis (AD). The synbiotic product contained Lactobacillus casei, Bifidobacterium lactis, Lactobacillus rhamnosus, Lactobacillus plantarum, fructooligosaccharide, galactooligosaccharide, and biotin. Patients were examined at baseline and at 8 weeks. Effectiveness of treatment was assessed with the Scoring Atopic Dermatitis (SCORAD) index. A total of 320 children (mean age 5.1 years, range 0-12 years) were included. The mean (SD) SCORAD index decreased from 45.5 (15.5) at baseline to 19.4 (14.6) at the end of treatment (P < 0.001), VAS score for pruritus decreased from 5.7 (2.2) to 2.3 (2.2) (P < 0.001), and VAS score for sleep decreased from 3.1 (2.5) to 1.1 (1.8) (P < 0.001). Percentage of children with moderate-severe disease decreased from 92.4% at baseline to 28.1% at week 8. In the multiple linear regression analysis, higher baseline SCORAD index (OR 0.51; 95% CI 0.41-0.61) and higher adherence (OR 7.29; 95% CI 1.85-12.73) were significantly associated with greater decrease in SCORAD index.Conclusion: Supplementation with the multistrain synbiotic product may improve AD in children. What is known: • Pediatric atopic dermatitis (AD) is a common, troublesome condition with limited treatment options, which has been shown to be associated with dysbiosis in the intestinal microflora. • Results of controlled clinical trials (RCTs) on the effect of probiotics in children with AD have been disparate, although overall, the data favor probiotics over placebo, with multistrain supplements associated with better improvements in AD. What is new: • The results of this observational, prospective, open-label, single-cohort study on 320 children with AD younger than 12 years old suggest that supplementation with multistrain synbiotics (Lactobacillus casei, Bifidobacterium lactis, Lactobacillus rhamnosus, Lactobacillus plantarum, fructooligosaccharide, galactooligosaccharide, and biotin) helps to improve AD symptoms in children. • More than 80% of children experienced improvement in AD symptoms, as measured by Severity Scoring of Atopic Dermatitis (SCORAD) index and assessed by parents and physicians. The main predictive factors for improvement was adherence to synbiotic treatment and high baseline SCORE index; the change in SCORAD did not depend on age, gender, presence of concomitant treatment, duration, and type of AD (persistent vs with flares), other concomitant allergies or history of parental allergy. SN - 1432-1076 UR - https://www.unboundmedicine.com/medline/citation/30259127/Effect_of_synbiotic_supplementation_on_children_with_atopic_dermatitis:_an_observational_prospective_study_ L2 - https://dx.doi.org/10.1007/s00431-018-3253-4 DB - PRIME DP - Unbound Medicine ER -